How much is the latest price of Mobotinib (Mobosetinib) per box in 2024?

Mobocertinib (Mobocertinib), also known as TAK-788, is an oral tyrosine kinase inhibitor (TKI) that specifically targets EGFR Patients with non-small cell lung cancer (NSCLC) with exon 20 insertion mutations. Such mutations often do not respond well to traditional EGFR-TKI treatments, so the development of mobotinib (mobosetinib) filled this treatment gap.

Mobotinib is now available in China, but it has not yet been included in the medical insurance catalog, so it is difficult to purchase it domestically. For more detailed information, please consult your local hospital pharmacy. In foreign countries, Mobotinib (Mobosetinib) has both original and generic drugs to choose from. Among them, the original drugs include the Hong Kong version produced by Japan's Takeda Pharmaceutical, and the price is about 7,000 to 8,000 yuan. Generic drugs mainly come from Laos and Bangladesh. The price is relatively cheap, about more than 3,000 yuan, which is about half lower than the original drug, and the drug ingredients are basically the same as the original drug.

The mechanism of action of Mobotinib is to prevent the growth and spread of cancer cells by selectively inhibiting the activity of abnormal EGFR. This selectivity makes it highly effective in inhibiting tumor cells carrying EGFR exon 20 insertion mutations, while having less impact on normal cells, thereby reducing side effects.

In clinical trials, Mobotinib (mobosetinib) showed significant anti-tumor activity. Multiple studies have shown that mobosetinibhas significant efficacy in patients who have previously received chemotherapy or other EGFR-TKI treatments that have failed. According to 2021 data, mobosetinib (mobosetinib) has significantly improved overall objective response rate (ORR) and progression-free survival (PFS).

Common side effects of Mobotinib include diarrhea, rash, nausea, and stomatitis, most of which are mild to moderate. For serious side effects such as interstitial lung disease andQTInterval prolongation requires close monitoring and prompt treatment.